There are no regulatory–approved effective therapies for treating microvascular dysfunction and/or diseases currently available. Examples of such diseases are 1) coronary microvascular angina, 2) microvascular stroke, 3) side effects of anti-cancer therapies (radiation, chemotherapy, kinase inhibitors, and antibody drugs) due to damages induced by abnormal microvascular function. Utilizing our strength in the field of microvascular research, Lucier Pharmaceuticals addresses such broad unmet clinical needs by focusing on the understanding of microvascular regulation and dysregulation from both functional and molecular perspectives. We develop novel therapies based on scientific evidence. With our research capability using the pig animal model, resembling the human organ system, Lucier provides pre-clinical services to the pharmaceutical industry to identify drug candidates and remedy microvascular abnormality for disease treatment.